** Kura Oncology's shares slide 17% to $13.20 premarket
** Co said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize blood cancer therapy drug ziftomenib
** Kura will lead the development of the drug, being evaluated for treating acute myeloid leukemia, a blood and bone marrow cancer
** Cos will jointly undertake commercialization and will equally share potential profits and losses, Kura said
** Kura to get upfront payment of $330 mln and up to $1.2 bln in total milestone payments as part of deal
** At least 4 brokerages cut PT
** Jefferies cuts PT to $28 from $32
** Views deal as strategically favorable for KURA
** "While the stock M&A premium will decrease in the near-term, the fundamental value is higher," brokerage says
** Avg rating of 15 brokerages is "buy"; median PT is $32 - LSEG data
** As of last close, stock up 10.6% YTD
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.